Drug de-escalation is primarily driven by the need to spare patients unnecessary toxicity and the associated side effects and repeated hospital visits. However, de-escalation strategies may also have the potential to reduce treatment costs.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- New practice guideline for fibromyalgia syndrome
Good times, bad times
- Findings from the TRACK-FA study
Neuroimaging biomarkers in Friedreich’s ataxia
- Doing sport without fear or risk
Doing sport without fear or risk
- Chronic inducible urticaria
What has stayed the same, what has changed?
- National Health Report 2025
Mental health in Switzerland
- Blastic plasmacytoid dendritic cell neoplasia
Rare malignancy from a dermatological perspective
- Prevention of skin cancer
UV protection and skin cancer screening – Update 2025
- Paroxysmal nocturnal hemoglobinuria